Uperio: Medicine to treat heart failure
Do not use within 36 hours after stopping ACEI, history of angioedema associated with ACEI angiotensin receptor blockers.
Uperio 50mg Each tablet: Sacubitril 24.3 mg, valsartan 25.7 mg.
Uperio 100mg Each tablet: Sacubitril 48.6 mg, valsartan 51.4 mg.
Uperio 200mg Each tablet: Sacubitril 97.2 mg, valsartan 102.8 mg.
Symptomatic heart failure in patients with systolic dysfunction.
Dosage/instructions for use
Initially 100 mg, 2 times/day. Patients with systolic blood pressure ≥100-110 mmHg/ not taking ACEIs or angiotensin II receptor blockers/ previously taking these drugs at low doses: use/recommendation/consider initiation of 50 mg twice /day. Double dose every 2 to 4 weeks to target dose of 200 mg twice daily as tolerated. If systolic blood pressure ≤ 95 mmHg, symptomatic hypotension, clinically significant hyperkalemia, renal dysfunction: adjust the dose of concomitant drugs, temporarily reduce dose/discontinue Uperio. Elderly patients: dose should be suitable for renal function; moderate-severe renal impairment, moderate hepatic impairment: 50 mg initially, twice daily; End-stage renal disease: not recommended. Children and adolescents < 18 years: Safety and efficacy have not been established.
How to use
Take with or without food.
Hypersensitivity to drug components. Concomitant use with ACEI, with aliskiren in patients with type 2 diabetes. Do not use within 36 hours after stopping treatment with ACEI. History of angioedema associated with ACEI/angiotensin receptor blockers. Severe liver failure, biliary cirrhosis, cholestasis. Pregnant.
Patients with renal artery stenosis, NYHA grade IV. Treatment should not be initiated or considered discontinued if serum potassium is >5.4 mmol/L. There may be an increased risk of hyperkalemia, although hypokalemia may also occur; especially in patients with renal failure, diabetes, hypoaldosteronism, high potassium diet, taking mineral corticosteroid antagonists. Discontinue use if angioedema occurs and should not be resumed. Driving and operating machinery. Consider stopping breastfeeding or discontinuing Uperio.
Very common: hyperkalemia, hypotension, impaired renal function. Common: anemia; hypokalemia, hypoglycemia; dizziness, headache, fainting; dizziness; orthostatic hypotension; cough; diarrhea, nausea, gastritis; CKD; fatigue, weakness.
Contraindications: ACEI (may increase risk of angioedema), aliskiren in patients with type 2 diabetes. Not recommended: angiotensin II receptor blockers (due to the angiotensin II receptor blocker effect of Uperio), aliskiren on renal failure patients. Consider combination: statin (increases statin and metabolite concentrations), PDE5 inhibitor (causes more potent hypotension). Possible interactions with potassium-sparing diuretics (eg, triamterene, amiloride), mineralocorticoid receptor antagonists (eg, spironolactone, eplerenone), potassium supplements, potassium salts: increase serum potassium and creatinine concentrations. ; NSAIDs including COX-2: increased risk of worsening of renal function; lithium: reversible increase in serum lithium concentration and toxicity; OATP1B1, OATP1B3, OAT3 inhibitors (eg, rifampin, cyclosporin) or MPR2 (eg ritonavir): increased circulating levels of the metabolite sacubitrilat or valsartan.
Angiotensin II receptor antagonists [Angiotensin II Antagonists]
Superio 100mg. Film-coated tablets: 2 × 14's.
Superio 200mg. Film-coated tablets: 4 × 7's.
Uperio 50mg. Film-coated tablets: 2 × 14's.